Key result
Chemotherapy for primary breast angiosarcoma shows ~75% mortality from disease progression.
Observational (n=4)
No
Primary breast angiosarcoma is a rare, aggressive malignancy with poor prognosis despite multimodal treatment.
Retrospective series underscore poor outcomes in primary breast angiosarcoma; larger prospective studies needed to guide management.
INTRODUCTION: Primary angiosarcoma of the breast is a rare entity with incidence of less than 0.05% of all malignant breast neoplasms. It occurs in young females without any associated risk factors. The tumor behaves aggressively and has a poor prognosis compared to invasive ductal carcinoma. METHOD: It was a retrospective observational study done at a tertiary cancer center from January 2012 to December 2016. The medical records of patients diagnosed with primary breast angiosarcoma were reviewed for the study. Clinicopathological profile, treatment, and the outcomes were analyzed. RESULTS: Four patients were diagnosed with primary breast angiosarcoma out of 2560 breast cancer patients seen over a period of 5 years. Two had metastatic disease at presentation. Among four patients, two underwent surgery of the primary tumor, whereas, all received chemotherapy either as adjuvant or palliative setting. One patient received adjuvant radiation therapy. Three patients received 2nd line and one received 3rd line chemotherapy on disease progression. After a median follow-up of 18 months one patient was surviving on 3rd line chemotherapy with trabectedin. Other three succumbed to disease after progression. CONCLUSION: Due to a small number of this malignancy randomized studies are difficult to perform and optimum treatment strategy still need to be defined.
No takes yet. Share an insight, caveat, or question.
Lokanatha et al. (2017) conducted an observational in Primary breast angiosarcoma (n=4). Primary breast angiosarcoma diagnosis and treatment was evaluated on Outcomes (survival and disease progression). Among 4 patients with primary breast angiosarcoma, 3 succumbed to disease progression and 1 survived on 3rd-line chemotherapy after a median follow-up of 18 months.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: